miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint
Resistance to chemotherapy occurs in many ovarian cancer cases. Here, the authors show that mir-424(322) expression restores the sensitivity of ovarian cancer cells to chemotherapy by blocking the PD-L1 immune checkpoint, and find that combining immunotherapy and chemotherapy has a synergistic effec...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2016-05-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/ncomms11406 |
| _version_ | 1818420232185708544 |
|---|---|
| author | Shaohua Xu Zhen Tao Bo Hai Huagen Liang Ying Shi Tao Wang Wen Song Yong Chen Jun OuYang Jinhong Chen Fanfei Kong Yishan Dong Shi-Wen Jiang Weiyong Li Ping Wang Zhiyong Yuan Xiaoping Wan Chenguang Wang Wencheng Li Xiaoping Zhang Ke Chen |
| author_facet | Shaohua Xu Zhen Tao Bo Hai Huagen Liang Ying Shi Tao Wang Wen Song Yong Chen Jun OuYang Jinhong Chen Fanfei Kong Yishan Dong Shi-Wen Jiang Weiyong Li Ping Wang Zhiyong Yuan Xiaoping Wan Chenguang Wang Wencheng Li Xiaoping Zhang Ke Chen |
| author_sort | Shaohua Xu |
| collection | DOAJ |
| description | Resistance to chemotherapy occurs in many ovarian cancer cases. Here, the authors show that mir-424(322) expression restores the sensitivity of ovarian cancer cells to chemotherapy by blocking the PD-L1 immune checkpoint, and find that combining immunotherapy and chemotherapy has a synergistic effect. |
| first_indexed | 2024-12-14T12:51:11Z |
| format | Article |
| id | doaj.art-83393a4ad9904862b71afa90aa143e94 |
| institution | Directory Open Access Journal |
| issn | 2041-1723 |
| language | English |
| last_indexed | 2024-12-14T12:51:11Z |
| publishDate | 2016-05-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Nature Communications |
| spelling | doaj.art-83393a4ad9904862b71afa90aa143e942022-12-21T23:00:40ZengNature PortfolioNature Communications2041-17232016-05-017111310.1038/ncomms11406miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpointShaohua Xu0Zhen Tao1Bo Hai2Huagen Liang3Ying Shi4Tao Wang5Wen Song6Yong Chen7Jun OuYang8Jinhong Chen9Fanfei Kong10Yishan Dong11Shi-Wen Jiang12Weiyong Li13Ping Wang14Zhiyong Yuan15Xiaoping Wan16Chenguang Wang17Wencheng Li18Xiaoping Zhang19Ke Chen20Department of Gynecology, Shanghai First Maternity and Infant Hospital, Tongji University School of MedicineDepartment of Radiation Oncology, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer institute & Hospital, National Clinical Research Center of CancerDepartment of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and TechnologyEmergency Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Gynecology, Changzhou Maternal and Child Health Hospital Affiliated to Nanjing Medical UniversityDepartment of Gynecology, Shanghai First Maternity and Infant Hospital, Tongji University School of MedicineDepartment of Gynecology, Shanghai First Maternity and Infant Hospital, Tongji University School of MedicineDepartment of Gynecology, Changzhou Maternal and Child Health Hospital Affiliated to Nanjing Medical UniversityDepartment of Biomedical Science, Mercer University School of MedicineDepartment of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Radiation Oncology, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer institute & Hospital, National Clinical Research Center of CancerDepartment of Radiation Oncology, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer institute & Hospital, National Clinical Research Center of CancerDepartment of Gynecology, Shanghai First Maternity and Infant Hospital, Tongji University School of MedicineKey Laboratory of Tianjin Radiation and Molecular Nuclear Medicine, Institute of Radiation Medicine, Peking Union Medical College & Chinese Academy of Medical SciencesDepartment of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyResistance to chemotherapy occurs in many ovarian cancer cases. Here, the authors show that mir-424(322) expression restores the sensitivity of ovarian cancer cells to chemotherapy by blocking the PD-L1 immune checkpoint, and find that combining immunotherapy and chemotherapy has a synergistic effect.https://doi.org/10.1038/ncomms11406 |
| spellingShingle | Shaohua Xu Zhen Tao Bo Hai Huagen Liang Ying Shi Tao Wang Wen Song Yong Chen Jun OuYang Jinhong Chen Fanfei Kong Yishan Dong Shi-Wen Jiang Weiyong Li Ping Wang Zhiyong Yuan Xiaoping Wan Chenguang Wang Wencheng Li Xiaoping Zhang Ke Chen miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint Nature Communications |
| title | miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint |
| title_full | miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint |
| title_fullStr | miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint |
| title_full_unstemmed | miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint |
| title_short | miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint |
| title_sort | mir 424 322 reverses chemoresistance via t cell immune response activation by blocking the pd l1 immune checkpoint |
| url | https://doi.org/10.1038/ncomms11406 |
| work_keys_str_mv | AT shaohuaxu mir424322reverseschemoresistanceviatcellimmuneresponseactivationbyblockingthepdl1immunecheckpoint AT zhentao mir424322reverseschemoresistanceviatcellimmuneresponseactivationbyblockingthepdl1immunecheckpoint AT bohai mir424322reverseschemoresistanceviatcellimmuneresponseactivationbyblockingthepdl1immunecheckpoint AT huagenliang mir424322reverseschemoresistanceviatcellimmuneresponseactivationbyblockingthepdl1immunecheckpoint AT yingshi mir424322reverseschemoresistanceviatcellimmuneresponseactivationbyblockingthepdl1immunecheckpoint AT taowang mir424322reverseschemoresistanceviatcellimmuneresponseactivationbyblockingthepdl1immunecheckpoint AT wensong mir424322reverseschemoresistanceviatcellimmuneresponseactivationbyblockingthepdl1immunecheckpoint AT yongchen mir424322reverseschemoresistanceviatcellimmuneresponseactivationbyblockingthepdl1immunecheckpoint AT junouyang mir424322reverseschemoresistanceviatcellimmuneresponseactivationbyblockingthepdl1immunecheckpoint AT jinhongchen mir424322reverseschemoresistanceviatcellimmuneresponseactivationbyblockingthepdl1immunecheckpoint AT fanfeikong mir424322reverseschemoresistanceviatcellimmuneresponseactivationbyblockingthepdl1immunecheckpoint AT yishandong mir424322reverseschemoresistanceviatcellimmuneresponseactivationbyblockingthepdl1immunecheckpoint AT shiwenjiang mir424322reverseschemoresistanceviatcellimmuneresponseactivationbyblockingthepdl1immunecheckpoint AT weiyongli mir424322reverseschemoresistanceviatcellimmuneresponseactivationbyblockingthepdl1immunecheckpoint AT pingwang mir424322reverseschemoresistanceviatcellimmuneresponseactivationbyblockingthepdl1immunecheckpoint AT zhiyongyuan mir424322reverseschemoresistanceviatcellimmuneresponseactivationbyblockingthepdl1immunecheckpoint AT xiaopingwan mir424322reverseschemoresistanceviatcellimmuneresponseactivationbyblockingthepdl1immunecheckpoint AT chenguangwang mir424322reverseschemoresistanceviatcellimmuneresponseactivationbyblockingthepdl1immunecheckpoint AT wenchengli mir424322reverseschemoresistanceviatcellimmuneresponseactivationbyblockingthepdl1immunecheckpoint AT xiaopingzhang mir424322reverseschemoresistanceviatcellimmuneresponseactivationbyblockingthepdl1immunecheckpoint AT kechen mir424322reverseschemoresistanceviatcellimmuneresponseactivationbyblockingthepdl1immunecheckpoint |